Contact US
Aboutlearninvestteamcontact

Invest

Press releases
Stroke video
presentation
financial
documentation

Press Releases

Latest Nobel Prize Validates Bioxytran at the Forefront of Scientific Discovery
The Nobel Laureates identified a genetic switch called hypoxia-inducible factor (HIF) that determines how cells adapt when oxygen levels drop. When oxygen levels are low and HIF is activated cells reduce their metabolic rates; this is important for short-term survival, but extended anaerobic metabolism can result in cell death and also causes lactic acid accumulation that harms tissues and organs.
October 16, 2019
Bioxytran Inc. Appoints Two Investment Bankers from Westbury Group to Its Advisory Board
BioxyTran announced today that it has invited John Jensen and Dr. Patrick Huddie from the Westbury Group to join Bioxytran’s Advisory Board to provide insight into capital markets, strategic partnerships and licensing opportunities, particularly in relation to the company’s listing strategy.
September 16, 2019
Bioxytran Inc. Announces Appointment of Dr. Hana Chen-Walden to Scientific Advisory Board
BioxyTran Inc announced today that it has retained Dr. Hana Chen-Walden, MD, BIRA Diploma in Regulatory Affairs, to join Bioxytran’s Scientific Advisory Board to assist designing the clinical trial protocol the company’s for Bioxytran’s flagship drug, BXT-25.
August 8, 2019
see all

Stroke Video

Presentation

presentation

Financial Information

press release
stock data
Historical Data
Historical stock Data
sec filing

Documentation

presentation
fact sheet
charter of auditors
Avise Analytics Report

Sign up for
BioXyTran Updates

Site
Terms of Sale
Terms of Use
Privacy Policy
Careers
233 Needham Street
Suite 300
Newton, MA, 02464
617-454-1199
info@bioxytraninc.com
Follow us on Twitter
Follow us on Facebook
All statements and expressions are the sole opinion of the editor and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.
© 2019 BioXyTran Inc.. All Rights Reserved